The Rational for a TB Vaccine

8/20/2019 The Rational for a TB Vaccine

http://slidepdf.com/reader/full/the-rational-for-a-tb-vaccine 1/59

Matt Feldman MSc MA

Senior Manager, StrategicCommunications

Lung Health Media TrainingCape Town, South AfricaDecember 2, 2 !"

TuberculosisHistor#, $ow, and %h# the Future &e'uires $ew T()accines



About Aeras* A $on+pro t (iotechAd-ancing T( )accines for the %orld

Aeras wor.s through partnershipsin both the public and pri-atesectors, with indi-iduals, researchorgani/ations, academicinstitutions, funders, polic#ma.ersand others around the world tode-elop new, e0ecti-e T( -accines1



nfectious Diseases Ha-e Shaped Ci-ili/ations

460-377 BCEHippocrates

1104-11104lague

1350 BCESmallpo5

165-180Antonine 4lague



)accines Ha-e Turned the Tides of Histor#

19604olio

1980Measles

1967Smallpo5



6Tuberculosis toda# is humanit#7s greatest .iller,and it is out of control in man# parts of the world1

The disease, pre-entable and treatable, has beengrossl# neglected and no countr# is immune toit18

• Arati 9ochi, Manager %H: Tuberculosis 4rogram, !;;3



The %orld7s <! nfectious Disease 9iller in Histor#

Source* $ature> %H:, 2 !3> %H:,



Source*



A lobal 4roblem

Source



A BS 4roblem* 2 !" T( Cases



Sourc



5tensi-el# Drug+&esistant T( E D&+T(G* 6 bola with%ings8• Airborne

transmission li.e acommon cold, withmortalit# similar to

bola E3 +? G• Found in ! "I

countries• At least 25 as man#

cases E 3,2 G last#ear as the totalnumber of cases of

bola 2 2 =



Drug &esistance* A Matter of Time

Source* Mar#



)accines* The Future of Fighting Tuberculosis



(C * Most %idel# Bsed )accine in the %orld

!;@



How Could )accines Halt T(J

Infected individuals

Preventingtransmissioinfection

Blocking prto infectiou

Treating ansterilizing a

A

B

CInfectious TB

Transmission

A2B

C

Transmissi on cycle

breakpoint

s

A1 Breakpoints



The 4otential of $ew T( )accines

• oal* de-elop new T( -accines that

would* – (e safer and more e0ecti-e in pre-enting T(

in children, adolescents and adults, includingpeople with H )

– 4rotect against all forms of T( K including MD&and D&

– &educe the cost and burden of T( on patients,healthcare s#stems and national economies



4ro ected Acceleration of T( ncidence Decline*limination &e'uires a )accine

Source* %H:, 2 ! > Stop T( 4artnership,

Introduce new vaccine,new prop !"a#i$

At the cdeclineuntil 2!%H: tarcases pepopulat



Funding 4riorities Ha-e $ot Matched Morbidit# Mortalit#

T( has recei-ed signi cantl# less funding in the last ! #ears compared to H ) andmalaria

Sources* %H:, 2 !2> $ature, 2 !3> H



The 4ublic Health mpact of $ew T( )accines



The lobal Clinical 4ipeline of T( )accineCandidates

• Nes, there are T(-accines inde-elopment

• 4rogress has beenmade since 2 ,when the rst new T(-accine was tested

• Since then, 3 Iclinical trials aroundthe world



Aeras7s lobal 0orts



The lobal Clinical 4ipeline of T( )accineCandidates

4hase 4hase a 4hase b 4hase

DA&+; !Dartmouth, Aeras

&BTArchi-el Farma, S1L

)4M ! 2S , Ma5 4lanc., )4M, T()

Vaccae ™

Anhui Ohifei Longcom

MT()AC (iofabri, T() , Oaragosa

H!PH"=* C3!SS , )alne-a, Aeras

M?2 I AS !S9, Aeras

Ad" Ag@"AMcMaster, CanSino

H * C3!Sano 4asteur, SS , Aeras

ChAd:5!1@"A P M)A@"A

:5ford, (irmingham

D;3 I LA+S

D& , %ellcome Trust, Aeras

M)A@"A P M)A@"A E D,AerosolG

:5ford

T( P FLB+ L& (S4

)iral )ector

4rotein P Ad u-ant

M#cobacterial K %hole Cell or 5tract

4lease note* nformation is self+reported b# -accine sponsors1

Revised on Nov 6th, 2



Success &e'uires Di-ersit#

??"

%ira" %ector &!co'acte

(rotein)Ad*uvant

@

3=

:r* %h# #ou can7t rest rml# on a one+legged stool

Scienti c Scores

"



0ecti-e Decision Ma.ing*t Matters %hat Nou Don7t Do

• $o-el approaches help accelerate the learning cur-e – reater scienti c understandingPanswering .e# 'uestions – De ning and Di0erentiating )accine 4latforms

• Di-ersit# increases eQcienc# and the li.elihood of success• Success is based on transparenc#, trust, coordination and

collaboration among global sta.eholders• Better data + 'etter deci$ion- a in.



Lesson from bola* nno-ation Can HappenR

• The 2 ! bola outbrea.

accelerated -accinede-elopment* candidates enteredclinical trials

• HowJ – 4artnerships – 4olitical will – ncreased funding



Source* Treatment Action rou

Funding for T( )accine & Dis ust 2" of %hat7s $eeded

S



Ad-ocating for & D

• T( -accine & D is a long+term, high+ris. endea-our• %e need to engage the global communit# to grow interest

and support for T( -accine & D• $ew audiences, new demand, new funding



A lobal Campaign About the4eopleon the Front Lines of the T(

pidemic

T(Bnmas.ed



A %or.force at &is.

• Healthcare wor.ers are on the

front lines of the global T(epidemic, putting themsel-es atris. of T( e5posure and infectionon a dail# basis, as the# care forothers

• The# deser-e protection• %e need to start now



D#ing to Help* T( in Conte5t

• reater ris. of de-eloping T( than the general population* – BSA* 25 – High burden countries* 31"5

• South Africa* "5• &ussia* ! 5• ndia* "5+!!5

• Bp to @ of cases from occupational e5posure



Spar.ing Ad-ocac# and Act

The stories of healtwor.ers need to be hK and used to helpad-ance the cause oprotecting this criticimportant wor.force



T( Bnmas.ed* oals

• Mobili/e a global communit# ofhealthcare wor.ers K informed andempowered K to see. better protectionfrom T(

• mphasi/e T( pre-ention andprotection for healthcare wor.ers in theglobal T( dialogue

• Create a sustainable mo-ement, wherelocal ad-ocates can dri-e progress forshort+ and long+term solutions



(uilding on Success* 4:S D

• 4:S D lm series EAeras, 2 !3G was launched toignite attention around the need for new T( -accines

• ! , -iews, a-ailable in ; languages• Screened at 3 e-ents in != countries• nternational awards and media attention• /ow can we do 'etter



Campaign Components

• Documentar# Films – Di-erse stories, perspecti-es and geographies – Distributed with partners, online and at screenings – n+depth e5tras on .e# issues

• Thought LeadershipPMaterial De-elopment – 4ublication in peer+re-iewed ournal –

:p+eds, inUuencer engagement, educational materials

• :nline Social 4latform – ducation, sharing stories, empowering action – &eaching new audiences



)ideo* Susheela

( d



T( Bnmas.ed* mpact

• ncredible online -iewership• 4ositi-e responses across the

T( communit#• Content being used in new

and une5pected wa#s



Challenge* %hat healthcarewor.er stories are around #ouJ



The &ipple 0ect* The (road mpacts of T( )accine Clinical Trials

Th &i l 0 t



The &ipple 0ect

• Clinical trials are more than

ust the scienti c 'uestions1)alue e5tends far be#ond-accine science*

– obs – Capacit# building –

nfrastructure – Access to healthcare – Communit# engagement

Th &i l 0 t



The &ipple 0ect

Communicating theof T( -accine trials athe need for additionsupport to continue important wor.1



)ideo* Mar. Hatherill

Challenge* %hat bene ts would T( -accine & D



bring to #our communitiesJ• %h# should #our polic# ma.ers and donors support this

wor.J• %hat bene ts would #our communities seeJ• How could this become a realit#J

Matt Feldman MSc MA



Senior Manager, Strategic

Communications

mfeldmanVaeras1org

The Rational for a TB Vaccine

Documents

Transcript of The Rational for a TB Vaccine